[go: up one dir, main page]

EP3512421A4 - Méthode et système de caractérisations de panel - Google Patents

Méthode et système de caractérisations de panel Download PDF

Info

Publication number
EP3512421A4
EP3512421A4 EP17851735.5A EP17851735A EP3512421A4 EP 3512421 A4 EP3512421 A4 EP 3512421A4 EP 17851735 A EP17851735 A EP 17851735A EP 3512421 A4 EP3512421 A4 EP 3512421A4
Authority
EP
European Patent Office
Prior art keywords
systems
methods
panel characterization
characterization
panel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17851735.5A
Other languages
German (de)
English (en)
Other versions
EP3512421A1 (fr
Inventor
Daniel Almonacid
Laurens KRAAL
Francisco OSSANDON
Juan Pablo CARDENAS
Jessica RICHMAN
Zachary APTE
Elisabeth BIK
Audrey Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogen Inc
Original Assignee
Psomagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/606,743 external-priority patent/US10803991B2/en
Application filed by Psomagen Inc filed Critical Psomagen Inc
Publication of EP3512421A1 publication Critical patent/EP3512421A1/fr
Publication of EP3512421A4 publication Critical patent/EP3512421A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Primary Health Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
EP17851735.5A 2016-09-16 2017-09-18 Méthode et système de caractérisations de panel Pending EP3512421A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395939P 2016-09-16 2016-09-16
US15/606,743 US10803991B2 (en) 2014-10-21 2017-05-26 Method and system for microbiome-derived diagnostics and therapeutics
US201762520058P 2017-06-15 2017-06-15
US201762525379P 2017-06-27 2017-06-27
PCT/US2017/052098 WO2018053443A1 (fr) 2016-09-16 2017-09-18 Méthode et système de caractérisations de panel

Publications (2)

Publication Number Publication Date
EP3512421A1 EP3512421A1 (fr) 2019-07-24
EP3512421A4 true EP3512421A4 (fr) 2021-08-11

Family

ID=61619786

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17851735.5A Pending EP3512421A4 (fr) 2016-09-16 2017-09-18 Méthode et système de caractérisations de panel

Country Status (11)

Country Link
EP (1) EP3512421A4 (fr)
JP (1) JP7114091B2 (fr)
KR (1) KR102486181B1 (fr)
CN (1) CN109715059A (fr)
AU (1) AU2017326564A1 (fr)
BR (1) BR112019005025A8 (fr)
CA (1) CA3036994A1 (fr)
CO (1) CO2019003713A2 (fr)
SG (1) SG11201901726QA (fr)
WO (1) WO2018053443A1 (fr)
ZA (1) ZA201901371B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109943636B (zh) * 2019-04-11 2020-01-24 上海宝藤生物医药科技股份有限公司 一种结直肠癌微生物标志物及其应用
CN110669818B (zh) * 2019-10-30 2021-08-24 中南大学 多发性骨髓瘤肠道微生物标志物及应用和检测制剂
KR102373889B1 (ko) * 2020-01-23 2022-03-15 주식회사 에이치이엠파마 장내 환경 개선을 위한 맞춤형 솔루션을 제공하는 방법 및 서버
WO2022160358A1 (fr) * 2021-02-01 2022-08-04 苏州大学附属儿童医院 Utilisation de micro-organisme intestinal comme marqueur de dysplasie broncho-pulmonaire chez un nourrisson prématuré
AU2022216551B2 (en) * 2021-02-03 2025-04-17 Tata Consultancy Services Limited Method and system for designing personalized therapeutics and diet based on functions of microbiome
KR102304402B1 (ko) * 2021-03-26 2021-09-24 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 비만 여부를 판별하는 방법 및 진단 장치
WO2023053703A1 (fr) 2021-09-29 2023-04-06 富士フイルム株式会社 Procédé de sélection de caractéristique mesurable et préférable, programme pour sélectionner une caractéristique mesurable et préférable, et dispositif de sélection de caractéristique mesurable et préférable
WO2023171482A1 (fr) 2022-03-09 2023-09-14 富士フイルム株式会社 Procédé, dispositif et programme
CN117838736B (zh) * 2024-01-29 2024-06-14 吉林省农业科学院(中国农业科技东北创新中心) 凝结芽孢杆菌ja845在制备预防和/或治疗抗动脉粥样硬化药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112352A2 (fr) * 2014-01-25 2015-07-30 uBiome, Inc. Procédé et système d'analyse du microbiome
WO2016065075A1 (fr) * 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
WO2016168352A1 (fr) * 2015-04-13 2016-10-20 uBiome, Inc. Procédé et système pour diagnostics et thérapies dérivés du microbiome pour affections associées à des éléments taxonomiques du microbiome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US10633714B2 (en) * 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
EP2876167A1 (fr) * 2013-11-21 2015-05-27 Institut Gustave Roussy Composition de la flore microbienne, comme marqueur de la réceptivité à la chimiothérapie et utilisation de modulateurs microbiens (pré-, pro- ou synbiotiques) pour améliorer l'efficacité d'un traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112352A2 (fr) * 2014-01-25 2015-07-30 uBiome, Inc. Procédé et système d'analyse du microbiome
WO2016065075A1 (fr) * 2014-10-21 2016-04-28 uBiome, Inc. Procédé et système de diagnostic et de thérapie fondés sur le microbiome
WO2016168352A1 (fr) * 2015-04-13 2016-10-20 uBiome, Inc. Procédé et système pour diagnostics et thérapies dérivés du microbiome pour affections associées à des éléments taxonomiques du microbiome

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALMONACID DANIEL E ET AL: "16S rRNA gene sequencing and healthy reference ranges for 28 clinically relevant microbial taxa from the human gut microbiome", PLOS ONE, 3 May 2017 (2017-05-03), pages e0176555, XP055820597, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176555> [retrieved on 20210702], DOI: 10.1371/journal.pone.0176555 *
ALMONACID DANIEL E. ET AL: "16S rRNA gene sequencing as a clinical diagnostic aid for gastroitestinal related conditions", BIORXIV, 31 October 2016 (2016-10-31), XP055820608, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/084657v1.> [retrieved on 20210702], DOI: 10.1101/084657 *
CHIH-MIN CHIU ET AL: "Clinical detection of human probiotics and human pathogenic bacteria by using a novel high-throughput platform based on next generation sequencing", JOURNAL OF CLINICAL BIOINFORMATICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 13 January 2014 (2014-01-13), pages 1, XP021175161, ISSN: 2043-9113, DOI: 10.1186/2043-9113-4-1 *
NADJA B. KRISTENSEN ET AL: "Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials", GENOME MEDICINE, vol. 8, no. 1, 10 May 2016 (2016-05-10), XP055439213, DOI: 10.1186/s13073-016-0300-5 *
OTT STEPHAN J ET AL: "Quantification of intestinal bacterial populations by real-time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 42, no. 6, 1 June 2004 (2004-06-01), pages 2566 - 2572, XP002428203, ISSN: 0095-1137, DOI: 10.1128/JCM.42.6.2566-2572.2004 *
PORETSKY RACHEL ET AL: "Strengths and Limitations of 16S rRNA Gene Amplicon Sequencing in Revealing Temporal Microbial Community Dynamics", PLOS ONE, vol. 9, no. 4, 8 April 2014 (2014-04-08), pages e93827, XP055820823, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093827> DOI: 10.1371/journal.pone.0093827 *
See also references of WO2018053443A1 *
SIMEONI UMBERTO ET AL: "Gut microbiota analysis reveals a marked shift to bifidobacteria by a a starter infant formula containing a synbiotic of bovine milk-derived a oligosaccharides and Bifidobacterium animalis subsp lactisCNCM I-3446", ENVIRONMENTAL MICROBIOLOGY, vol. 18, no. 7, 2 December 2015 (2015-12-02), pages 2185 - 2195, XP055820498, Retrieved from the Internet <URL:https://sfamjournals.onlinelibrary.wiley.com/doi/epdf/10.1111/1462-2920.13108> [retrieved on 20210702], DOI: 10.1111/1462-2920.13144 *
THOMAS VINCENT ET AL: "Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies", FUTURE MICROBIOLOGY, FUTURE MEDICINE LTD, GB, vol. 10, no. 9, 1 January 2015 (2015-01-01), pages 1485 - 1504, XP009194769, ISSN: 1746-0913, DOI: 10.2217/FMB.15.87 *

Also Published As

Publication number Publication date
CA3036994A1 (fr) 2018-03-22
BR112019005025A8 (pt) 2023-03-21
AU2017326564A1 (en) 2019-03-28
ZA201901371B (en) 2019-11-27
BR112019005025A2 (pt) 2019-06-18
CN109715059A (zh) 2019-05-03
EP3512421A1 (fr) 2019-07-24
KR20190055127A (ko) 2019-05-22
KR102486181B1 (ko) 2023-01-06
SG11201901726QA (en) 2019-03-28
JP2019528729A (ja) 2019-10-17
JP7114091B2 (ja) 2022-08-08
CO2019003713A2 (es) 2019-04-30
WO2018053443A1 (fr) 2018-03-22

Similar Documents

Publication Publication Date Title
EP3638096A4 (fr) Procédés et systèmes pour chirurgie du glaucome guidée par oct
EP3679683A4 (fr) Systèmes et procédés de fourniture d&#39;enregistrements immuables
EP3535415A4 (fr) Méthodes et systèmes de détection d&#39;une tumeur
EP3466031A4 (fr) Systèmes et procédés de détection d&#39;anomalie
EP3665858A4 (fr) Système et procédé de vérification d&#39;interactions
EP3720392C0 (fr) Systèmes et procédés d&#39;alignement orthopédiques multi-planaires
EP3448487A4 (fr) Embouts de conduits et systèmes et procédés d&#39;utilisation
EP3673647A4 (fr) Procédés et systèmes de capture d&#39;image
EP3631919A4 (fr) Systèmes et procédés de modification des caractéristiques de faisceau
EP3485235C0 (fr) Systèmes et procédés de surveillance d&#39;égout
EP3857260A4 (fr) Procédés et systèmes de cartographie de rétroréflecteurs
EP3586324A4 (fr) Procédés et systèmes de détection d&#39;incendie
EP3286359C0 (fr) Procédés et systèmes pour une classification taxinomique multiple
EP3468498A4 (fr) Systèmes et procédés de télé-chirurgie assistée par ordinateur
EP3160661C0 (fr) Système et procédés pour l&#39;anti-encrassement biologique
EP3271801C0 (fr) Systèmes et procédés de collaboration en ligne
EP3796116C0 (fr) Procédé et système de fabrication additive-ablative
EP3545696C0 (fr) Systèmes et procédés d&#39;affichage d&#39;image dans plusieurs dispositifs
EP3463169A4 (fr) Systèmes et procédés de réparation de défauts tissulaires
EP2976687A4 (fr) Systèmes et procédés d&#39;accueil d&#39;uav
EP3512421A4 (fr) Méthode et système de caractérisations de panel
EP3104817C0 (fr) Systemes et procedes de cicatrisation tissulaire
EP3218837C0 (fr) Systèmes et procédés pour espaces intelligents
EP3589330A4 (fr) Méthodes et systèmes de modification d&#39;adn
EP3308608C0 (fr) Système et procédé de suivi visuel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
19U Interruption of proceedings before grant

Effective date: 20191011

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20201201

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PSOMAGEN, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61B0005050000

Ipc: G01N0033500000

A4 Supplementary search report drawn up and despatched

Effective date: 20210714

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20210708BHEP

Ipc: G16H 50/20 20180101ALI20210708BHEP

Ipc: G16B 40/10 20190101ALI20210708BHEP

Ipc: A61B 5/05 20210101ALI20210708BHEP

Ipc: A61B 1/00 20060101ALI20210708BHEP

Ipc: C12Q 1/04 20060101ALI20210708BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MACROGEN INC.